Related Experiment Videos
Potentiation of actinomycin D or adriamycin antitumor activity with DNA
Abstract:
Several antitumor agents known to bind DNA were complexed with this macromolecule and tested for activity against experimental animal tumor systems. Combination studies with these agents and DNA were carried out at the same time. Actinomycin D activity against the P388 lymphocytic leukemia in BALB/c X DBA/2 F1 mice was significantly potentiated by calf thymus DNA, both when complexed and when injected in combination. The DNA could be given as much as 4 hr before or after the antibiotic and still give potentiation. Synergism was also obtained when the DNA was autoclaved prior to complexing and/or injecting. Similarly, adriamycin activity against the L1210 lymphoid leukemia in DBA/2 mice was significantly potentiated by autoclaved herring sperm DNA, both as a complex and when injected in combination. When above-optimal levels of adriamycin were complexed with autoclaved herring sperm DNA and injected into BALB/c mice inoculated with the Madison 109 alveogenic carcinoma, the early lethality was delayed and antitumor activity was sometimes observed. Herring sperm DNA injected alone also had antitumor activity against the Madison 109 tumor. Similarly, activity was obtained against this tumor system with calf thymus DNA and actinomycin D when injected alone. In addition, DNA, in combination and when complexed with actinomycin, prevented the toxicity observed with BALB/c mice, inoculated with the Madison 109 tumor, were given injections of an above-optimal dose of this antibiotic.
Insights
DNA potentiates antitumor agent efficacy. Complexing or combining DNA with actinomycin D and adriamycin significantly enhanced their activity against various animal tumors, even reducing toxicity.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Antitumor agents often interact with DNA.
- Investigating DNA as a potentiator for existing chemotherapeutics is a novel approach.
Purpose of the Study:
- To evaluate the synergistic effects of DNA when combined or complexed with antitumor agents.
- To assess the impact of DNA on the efficacy and toxicity of actinomycin D and adriamycin in animal tumor models.
Main Methods:
- Complexing antitumor agents (actinomycin D, adriamycin) with DNA (calf thymus, herring sperm).
- Administering complexes or combinations of agents and DNA in experimental animal tumor systems (P388 leukemia, L1210 leukemia, Madison 109 carcinoma).
- Evaluating antitumor activity, potentiation, synergism, and toxicity.
Main Results:
- Calf thymus DNA significantly potentiated actinomycin D against P388 leukemia, with potentiation observed up to 4 hours before or after the drug.
- Autoclaved herring sperm DNA synergistically enhanced adriamycin activity against L1210 leukemia.
- DNA complexation with adriamycin delayed lethality and showed antitumor activity against Madison 109 carcinoma, with DNA alone also exhibiting activity.
- DNA reduced the toxicity of supra-optimal adriamycin doses.
Conclusions:
- DNA can act as a potentiator and synergist for DNA-binding antitumor agents like actinomycin D and adriamycin.
- DNA complexation or combination therapy offers a promising strategy to enhance anticancer drug efficacy and mitigate toxicity.
- Further research into DNA-based drug delivery and potentiation is warranted for cancer treatment development.